Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your Favorites.
This session is in your Favorites. Click again to remove it.
Presentation Icons
ACG Award Winner
ACG Newsworthy Abstract
Registration Required
No CME
On-Demand Video
Livestream
Favorite
Email
Renee-Claude Mercier, PharmD
Gilead Sciences, Inc.
Poster(s):
P3779 - Final Results of MYR301: A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Up to 144 Weeks of Bulevirtide Monotherapy for Chronic Hepatitis Delta and 96 Weeks of Post-Treatment Follow-Up
Monday, October 27, 2025
10:30 AM - 4:00 PM
MT
P3780 - Achieving Undetectable Hepatitis Delta Virus RNA at End of Therapy With Bulevirtide 10 Mg/day With or Without PegIFNα Is Strongly Associated With Posttreatment Virologic Response in Chronic Hepatitis Delta
Monday, October 27, 2025
10:30 AM - 4:00 PM
MT
P3781 - Predictors of Undetectable Hepatitis Delta Virus RNA at 48 Weeks After End of Treatment With Bulevirtide Monotherapy in the MYR 301 Study
Monday, October 27, 2025
10:30 AM - 4:00 PM
MT
Email Renee-Claude
